A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age

Registry ID

EUCTR2007-004020-20

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Merck & Co., Inc.

Start date

2007-10-25

Completion date

2010-01-05

Last update

2026-08-16

Conditions

• Herpes Zoster

Summary

To assess the impact of ZOSTAVAX™ on the development of HZ in subjects 50 to 59 years of age.

Locations

• , , Finland
• , , Belgium
• , , Germany

Related clinical trials

• Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
• Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine
• A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
• The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
• The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster
• A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

View on source registry